Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

LYEL

+ Watchlist+ Portfolio

Lyell Immunopharma, Inc.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$13.67
52-Week Range
$7.20 – $45.00
Market Cap
$444.70M
P/E (TTM)
—
EPS (TTM)
-12.61
Dividend Yield
0.00%
Advanced Metrics
Price/Book
1.77
PEG Ratio
—
Return on Equity
-97.79%
Return on Assets
-36.90%
Gross Margin
100.00%
Operating Margin
-1341693.40%
Profit Margin
0.00%
Current Ratio
4.02
Debt/Equity
0.23
Total Debt
$44.28M
Free Cash Flow
$-65.90M
Revenue Growth
-80.00%
Earnings Growth
—
Enterprise Value
$208.67M

Market Snapshot

About

Lyell Immunopharma, Inc. is a T-cell reprogramming company developing cell therapies for solid tumors. The company focuses on addressing T-cell exhaustion and enhancing the persistence and functionality of engineered T-cells for cancer treatment. Lyell combines synthetic biology and genetic reprogramming techniques to create next-generation adoptive cell therapies.